Skip to main content
Erschienen in: BMC Cancer 1/2021

Open Access 01.12.2021 | Correction

Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study

verfasst von: Shebli Atrash, Philippe Thompson-Leduc, Ming-Hui Tai, Shuchita Kaila, Kathleen Gray, Isabelle Ghelerter, Marie-Hélène Lafeuille, Patrick Lefebvre, Adriana Rossi

Erschienen in: BMC Cancer | Ausgabe 1/2021

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​s12885-021-08881-7.
Correction to: BMC Cancer 21, 1207 (2021)
https://doi.org/10.1186/s12885-021-08881-7
Following publication of the original article [1], it was identified that due to typesetting mistakes, an unfinalized version of the article were published. The following changes have been implemented.
1)
The corresponding author’s email address has been corrected: Philippe.​Thompson-Leduc@analysisgroup.​com
 
2)
In table 1, note 2, the full reference is: Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–9. https://​doi.​org/​10.​1200/​JCO.​2015.​61.​2267
 
3)
In table 2, note 3, the full reference is: Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–31. https://​doi.​org/​10.​1056/​NEJMoa1607751
 
4)
In table 3, note 1, the full reference is: Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e46. https://​doi.​org/​10.​1016/​S1470-2045(16)30206-6
 
5)
In table 4, note 2, the full reference is: Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e46. https://​doi.​org/​10.​1016/​S1470-2045(16)30206-6
 
6)
In the section, Treatment patterns of first daratumumab-based regimen, paragraph three: The text should not have been in bold typeface.
 
7)
In the section, Treatment patterns of first daratumumab-based regimen, paragraph three: “3.3 Clinical outcomes” Was removed from the end of the paragraph.
 
8)
In the abbreviations list, “3 L: Third line or later” was updated to “3 L+: Third line or later”
 
These corrections were typesetting errors and do not influence the results of this article. The publishers apologise for this error. The original article [1] has been updated.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
verfasst von
Shebli Atrash
Philippe Thompson-Leduc
Ming-Hui Tai
Shuchita Kaila
Kathleen Gray
Isabelle Ghelerter
Marie-Hélène Lafeuille
Patrick Lefebvre
Adriana Rossi
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2021
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-09015-9

Weitere Artikel der Ausgabe 1/2021

BMC Cancer 1/2021 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.